Based on the current pipeline of durable therapies, MIT research indicates ‘it’s not a big lift to cover the children and the adults in Medicaid for these products,’ Mark Trusheim says.

Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.

Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.

Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.